View Exam | PowerPak

1. Which of the following would be the most appropriate use of the Aspergillus spp. lateral flow device in the ICU setting?

A. To diagnose invasive pulmonary aspergillosis (IPA) in a patient who has already received antifungals B. To diagnose IPA in patients who are not on antifungals C. To exclude IPA D. No appropriate use, the LFA has not been studied in the ICU setting

2. You are evaluating a C glabrata isolate that has an MIC50 for fluconazole of 64 mcg/mL. The epidemiological cut-off value for the organism has been established as <32 mcg/mL. How can you characterize this isolate?

A. It most likely exhibits a resistance mechanism B. It falls within the test variation of MIC testing C. It would be classified as a wild-type organism D. It is not susceptible to fluconazole, even if the dose is increased

3. The detection level for T2 Candida is:

A. 15-20 CFU/mL B. 8-10 CFU/mL C. 1-3 CFU/mL D. 1 CFU/mL, regardless of the species

4. The proportion of inappropriate antifungal prescribing is highest for:

A. Prophylaxis B. Empiric C. Pre-emptive D. Tailored

5. Which is the correct dosing of fluconazole for candidemia/invasive candidiasis according to the 2016 IDSA candidiasis guidelines?

A. Fluconazole 150 mg daily B. Fluconazole 400 mg (6 mg/kg) daily C. For C glabrata infection: Fluconazole 600 mg (12 mg/kg) D. Fluconazole 800 mg (12 mg/kg) loading dose, then 400 mg (6 mg/kg) daily

6. Which of the following is the correct dosing for delayed-release posaconazole tablets?

A. 200 mg TID B. 400 mg bid C. 300 mg q12 hrs x 2 doses, then daily D. 400 mg q12 hrs x 2 doses, then daily

7. Regarding amphotericin B formulations:

A. The generic lipid formulations all incorporate liposomes B. The lipid release properties of amphotericin B lipid complex (ABLC) and liposomal amphotericin B are similar C. You can readily interchange doses among the generic lipid amphotericin B formulations D. The approvals of the generic lipid amphotericin B formulations are based on pharmacologic characteristics rather than efficacy studies

8. Which of the following is supportive of therapeutic drug monitoring?

A. Large and unpredictable variability of blood concentrations B. Measurements available, just not in real-time C. Relationship between blood concentrations and the effect on infected tissues is unknown D. Lack of studies exploring efficacy and toxicity associated with drug over- or under-dosing

9. Which of the following azole is a known substrate for P-glycoprotein?

A. Posaconazole B. Itraconazole C. Fluconazole D. Isavuconazole

10. In the SECURE trial, the proportion of patients experiencing treatment-emergent AEs was significantly higher with voriconazole vs isavuconazole for:

A. Skin/subcutaneous tissue disorders B. Eye disorders C. Hepatobiliary disorders D. All of the above

11. Which of the following are relevant strategies when prescribing antifungals in transplant patients?

A. Evaluate the enzyme systems involved carefully B. Consider adjusting the dose of the immunosuppressant when initiating the azole C. Reevaluate the dose of the immunosuppressant when you discontinue the azole D. All of the above

12. Most clinical guidelines recommend combination therapy for IPA:

A. In the setting of disease progression B. For patients with very high galactomannan levels C. For consideration in select patients D. In patients who failed another class of therapy first-line

13. According to the recently released IDSA guidelines for invasive aspergillosis, which of the following is a reasonable primary therapy (no contraindications present)

A. Micafungin B. Caspofungin C. Posaconazole D. Liposomal amphotericin B

14. Which of the following is FDA approved as a primary therapy for invasive mucormycosis?

A. Posaconazole B. Isavuconazole C. Liposomal amphotericin B D. Deferasirox

15. Regarding the management of breakthrough infections in patients who have received azole prophylaxis in the HSCT setting:

A. It is usually caused by an azole-resistant isolate B. Therapeutic drug monitoring is usually not helpful in this setting C. In the setting of blood culture positive for yeast, removal of the foreign body is recommended D. Fluconazole is usually an appropriate agent to use at yeast breakthrough

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following would be the most appropriate use of the Aspergillus spp. lateral flow device in the ICU setting?

2. You are evaluating a C glabrata isolate that has an MIC50 for fluconazole of 64 mcg/mL. The epidemiological cut-off value for the organism has been established as <32 mcg/mL. How can you characterize this isolate?

3. The detection level for T2 Candida is:

4. The proportion of inappropriate antifungal prescribing is highest for:

5. Which is the correct dosing of fluconazole for candidemia/invasive candidiasis according to the 2016 IDSA candidiasis guidelines?

6. Which of the following is the correct dosing for delayed-release posaconazole tablets?

7. Regarding amphotericin B formulations:

8. Which of the following is supportive of therapeutic drug monitoring?

9. Which of the following azole is a known substrate for P-glycoprotein?

10. In the SECURE trial, the proportion of patients experiencing treatment-emergent AEs was significantly higher with voriconazole vs isavuconazole for:

11. Which of the following are relevant strategies when prescribing antifungals in transplant patients?

12. Most clinical guidelines recommend combination therapy for IPA:

13. According to the recently released IDSA guidelines for invasive aspergillosis, which of the following is a reasonable primary therapy (no contraindications present)

14. Which of the following is FDA approved as a primary therapy for invasive mucormycosis?

15. Regarding the management of breakthrough infections in patients who have received azole prophylaxis in the HSCT setting:

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following would be the most appropriate use of the Aspergillus spp. lateral flow device in the ICU setting?

2. You are evaluating a C glabrata isolate that has an MIC50 for fluconazole of 64 mcg/mL. The epidemiological cut-off value for the organism has been established as <32 mcg/mL. How can you characterize this isolate?

3. The detection level for T2 Candida is:

4. The proportion of inappropriate antifungal prescribing is highest for:

5. Which is the correct dosing of fluconazole for candidemia/invasive candidiasis according to the 2016 IDSA candidiasis guidelines?

6. Which of the following is the correct dosing for delayed-release posaconazole tablets?

7. Regarding amphotericin B formulations:

8. Which of the following is supportive of therapeutic drug monitoring?

9. Which of the following azole is a known substrate for P-glycoprotein?

10. In the SECURE trial, the proportion of patients experiencing treatment-emergent AEs was significantly higher with voriconazole vs isavuconazole for:

11. Which of the following are relevant strategies when prescribing antifungals in transplant patients?

12. Most clinical guidelines recommend combination therapy for IPA:

13. According to the recently released IDSA guidelines for invasive aspergillosis, which of the following is a reasonable primary therapy (no contraindications present)

14. Which of the following is FDA approved as a primary therapy for invasive mucormycosis?

15. Regarding the management of breakthrough infections in patients who have received azole prophylaxis in the HSCT setting:

« Return to Activity

Customers who Purchased
this Activity also Purchased